What is TAP?
The Treatment Access Platform (TAP) is an innovative solution designed to solve several major problems within the medical care industry; especially as patients have difficulty accessing new and applicable treatments.
The TAP follows Thai FDA regulations and provides new provisional medical care to patients through a limited number of qualified Tier 1 hospitals during early stages of technology market release.
In parallel with operating the TAP, ABC will continue its R&D and clinical trials for new therapeutics and diagnostics.
To account for the economic benefits and risks of developing a new drug, traditional pharmaceutical companies are left with seeking ONLY large addressable markets AND charging high premiums for the newly-developed interventions in order to recover their spending in R&D, regulations, and marketing. Naturally, USA and EU, with their large population sizes and high levels of medical expenditures, become the primary markets for all new medical innovations.
Using the unique and innovative fundraising strategy of an initial coin offering (ICO), ABC can meaningfully address such problems of market limitations and high drug costs caused by the pursuit of return of investment. More importantly, the TAP will grant participants exclusive and guaranteed access to treatments and diagnostics in early stage of market release.
will be Available on the TAP?
The TAP will provide technologies for cancers, neurological diseases, infectious diseases, vascular diseases, and metabolic diseases. ABC supports innovative diagnostics and various treatment modalities such as: gene and cell therapy, vaccines, and immunotherapy.
CONTACT US TO EXPLORE A PARTNERSHIP
Ascendant Biotech Corporation Ltd.
158/5 Aneckvanich Building (Rooms AC, 5th Floor) Sukhumvit 55 Road, Khlong Tan Nuea, Vadhana, Bangkok 10110
STAY TUNED FOR OUR LAUNCH ANNOUNCEMENT VIA